Table 3.
Results from multivariable linear regression analysis for the relationship between trial characteristics and enrollment rate of BIPOC groups
| Trial factors | Estimated β (95%CI) | P |
|---|---|---|
| Year of publication | ||
| 2000–2009 | Ref | - |
| 2010–2020 | 5.03 (0.31, 9.75) | 0.037 |
| Sample size ≥ 716a | − 1.82 (− 5.17, 1.54) | 0.287 |
| Diabetes type | ||
| Other | Ref | - |
| Type 2 diabetes | 2.59 (0.17, 5.01) | 0.036 |
| Enrollment location | ||
| Other | Ref | - |
| Ambulatory | − 5.60 (− 11.06, − 0.14 | 0.044 |
| Random type | ||
| Cluster | Ref | - |
| Individual | − 4.06 (− 18.11, 9.98) | 0.570 |
| Trial primary objective | ||
| Complication | Ref | - |
| Glucose control | 3.07 (− 2.06, 8.20) | 0.240 |
| Management/ Mixed | − 1.78 (− 6.39, 2.83) | 0.449 |
| Intervention | ||
| Type of intervention | ||
| Others | Ref | - |
| Medication | − 4.48 (− 10.41, 1.44) | 0.138 |
| Frequency of intervention | ||
| Others | Ref | - |
| Weekly/daily | − 1.73 (− 6.49, 3.03) | 0.476 |
| Duration of intervention > 6.5 montha | − 4.91 (− 8.56, − 1.27) | 0.008 |
| Follow-up | ||
| Type of follow-up | ||
| Others | Ref | - |
| Face-to-face | − 1.80 (− 5.97, 2.38) | 0.398 |
| Frequency of follow-up | ||
| Other | Ref | - |
| Weekly/ Monthly | 0.004 (− 5.57, 5.58) | 0.999 |
| Duration of follow-up > 12 monthsa | 0.07 (− 3.81, 3.96) | 0.970 |
| Funding source | ||
| Non-industry | Ref | - |
| Industry | − 0.42 (− 4.84, 4.00) | 0.853 |
aThe cut-off point was determined by using the median value
Ref reference category/level